Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

Recruiting

Back to Chronic Pulmonary Aspergillosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(37 sites)

Austria

Kepler University Hospital, Linz

Belgium

Brussels University Hospital, Brussels

UZ Gent, Ghent

University Hospital Leuven, Leuven

CHU UCL Namur, Yvoir

France

CHU Amiens Picardie, Amiens

Institut Coeur Poumon CHU, Lille

CHU Arnaud de Villeneuve, Montpellier

CHU Bordeaux, Pessac

CHU de Rouen, Rouen

Germany

Evangelische Lungenklinik Berlin, Berlin

University of Cologne, Cologne

Asklepios Lungenfachklinik Gauting, Gauting

Hungary

Országos Korányi Pulmonológiai Intézet, Budapest

Italy

University of Genova, San Martino Hospital, Genova

University of Pisa, Pisa

INMI Lazzaro Spallanzaniconsu, Roma

Humanitas Research Hospital, Rozzano

Netherlands

Radboud Universitair Medisch Centrum Stichting, Nijmegen

South Korea

Chonnam National University Hospital, Gwangju

Seoul National University Bundang Hospital, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Spain

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitari de Bellvitge, Barcelona

Vall d'Hebron Barcelona Hospital Campus, Barcelona

Ramón y Cajal Hospital, Madrid

Hospital Sant Joan de Deu de Martorell, Martorell

Hospital La Fe, Valencia

United Kingdom

Royal Papworth Hospital, Cambridge

University Hospitals of Derby and Burton, Derby

Western General Hospital, Edinburgh

Leeds Teaching Hospital, Leeds

Imperial College Hospital, London

Royal Brompton Hospital, Guy's and St. Thomas' Hospital, London

University College London (UCL) Hospitals, London

Manchester University Hospital, Manchester